Question: What is going on with Sirtex (SRX)? I am new in the share market.
Answer (Peter Switzer): Sirtex had a big run up in 2015 and it looks like the market is starting to question whether they can achieve dose sales increases of 20% per annum, plus also the challenges with clinical trials.
Broker Morgans recently wrote this (precis):
Morgans observes investors are starting to question the sustainability of 20% underlying volume growth. The broker does not believe that SIRFLOX results will boost sales. There are also headwinds from the US reimbursement environment. Morgans remains pessimistic about the slowing dose sales growth per treatment site and continues to believe portfolios should exit positions to limit downside risk. Reduce rating retained. Target is $17.60.
According to FN Arena, the broker consensus target price is $35.67 – with a range of $17.60 to $46.90. This is a huge range – which shows the divergent views on this stock. Sirtex is one of the more volatile health care stocks, and I would caution having a position in this stock unless you really understand the business well.
Question: What is a typical charge for a financial adviser to manage your self managed fund?
Answer (Paul Rickard): It would depend on a couple of factors, including the size of your fund and the number of members, and the complexity of the investment structures. While there is no standard, I would say that a typical ongoing advice fee is in the range of $3,000 to $5,000 per annum. If the adviser is doing other things – for example, accounting or administrative services like paying pensions or lodging tax returns, then these services could attract additional fees.
Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual. It does not constitute formal advice. Consider the appropriateness of the information in regards to your circumstances.
